Parthenon LLC Has $327,000 Position in Amgen Inc. (AMGN)
Parthenon LLC maintained its position in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, Holdings Channel reports. The institutional investor owned 2,147 shares of the medical research company’s stock at the end of the second quarter. Parthenon LLC’s holdings in Amgen were worth $327,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. FirstMerit Bank N A Trustee boosted its stake in Amgen by 5.3% in the first quarter. FirstMerit Bank N A Trustee now owns 32,630 shares of the medical research company’s stock valued at $4,893,000 after buying an additional 1,632 shares in the last quarter. Kelman Lazarov Inc. bought a new stake in Amgen during the first quarter valued at approximately $252,000. Carl Domino Inc boosted its stake in Amgen by 483.9% in the first quarter. Carl Domino Inc now owns 9,062 shares of the medical research company’s stock valued at $1,359,000 after buying an additional 7,510 shares in the last quarter. Narwhal Capital Management boosted its stake in Amgen by 2.5% in the first quarter. Narwhal Capital Management now owns 10,245 shares of the medical research company’s stock valued at $1,536,000 after buying an additional 250 shares in the last quarter. Finally, Raymond James Trust N.A. boosted its stake in Amgen by 59.9% in the first quarter. Raymond James Trust N.A. now owns 28,653 shares of the medical research company’s stock valued at $4,296,000 after buying an additional 10,739 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.13% on Tuesday, reaching $167.55. 2,797,603 shares of the company traded hands. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85. The firm’s 50 day moving average is $171.31 and its 200 day moving average is $161.60. The company has a market capitalization of $125.39 billion, a P/E ratio of 17.15 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. During the same quarter in the prior year, the business earned $2.57 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Analysts expect that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were given a dividend of $1.00 per share. This represents a $4.00 annualized dividend and a yield of 2.39%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s payout ratio is 40.90%.
Several equities analysts recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $190.00 price objective on shares of Amgen in a research report on Thursday, September 22nd. Jefferies Group reaffirmed a “buy” rating and set a $198.00 price objective on shares of Amgen in a research report on Tuesday, August 23rd. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $171.34 price objective on the stock in a research report on Wednesday, August 3rd. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Finally, Credit Suisse Group AG set a $206.00 price objective on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, September 17th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the stock. Amgen presently has an average rating of “Buy” and a consensus target price of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.